RxSight, Inc. (NASDAQ:RXST) Director Shweta Maniar Sells 3,519 Shares

RxSight, Inc. (NASDAQ:RXST) Director Shweta Maniar sold 3,519 shares of the company’s stock in a transaction that occurred on Wednesday, January 22nd. The stock was sold at an average price of $30.87, for a total transaction of $108,631.53. Following the transaction, the director now directly owns 7,383 shares of the company’s stock, valued at $227,913.21. This trade represents a 32.28 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Shweta Maniar also recently made the following trade(s):

• On Tuesday, November 26th, Shweta Maniar sold 3,782 shares of RxSight stock. The stock was sold at an average price of $45.88, for a total value of $173,518.16.

RxSight Trading Up 0.1 %

Shares of RxSight stock opened at $32.50 on Tuesday. The stock has a market capitalization of $1.31 billion, a price-to-earnings ratio of -39.16 and a beta of 1.20. RxSight, Inc. has a twelve month low of $26.29 and a twelve month high of $66.54. The business’s 50 day simple moving average is $37.37 and its 200-day simple moving average is $45.65.

RxSight (NASDAQ:RXST) last posted its earnings results on Thursday, November 7th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.18). RxSight had a negative net margin of 23.92% and a negative return on equity of 14.00%. The firm had revenue of $35.31 million for the quarter, compared to analyst estimates of $35.15 million. During the same period in the previous year, the firm earned ($0.35) earnings per share. Sell-side analysts predict that RxSight, Inc. will post -0.7 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on RXST. UBS Group assumed coverage on RxSight in a research note on Friday, December 6th. They issued a “buy” rating and a $52.00 target price for the company. Needham & Company LLC reissued a “buy” rating and set a $66.00 target price on shares of RxSight in a research report on Monday, January 13th. Jefferies Financial Group assumed coverage on shares of RxSight in a report on Tuesday, October 29th. They set a “buy” rating and a $72.00 price target for the company. Stifel Nicolaus cut their price objective on shares of RxSight from $40.00 to $35.00 and set a “hold” rating on the stock in a report on Monday, January 13th. Finally, Wells Fargo & Company lowered their target price on RxSight from $42.00 to $40.00 and set an “equal weight” rating for the company in a research note on Monday, January 13th. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $58.13.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of RXST. KBC Group NV lifted its holdings in RxSight by 71.0% in the fourth quarter. KBC Group NV now owns 2,107 shares of the company’s stock worth $72,000 after purchasing an additional 875 shares during the period. Harbor Investment Advisory LLC bought a new stake in shares of RxSight during the 4th quarter worth about $52,000. Paragon Advisors LLC lifted its stake in shares of RxSight by 20.5% in the 4th quarter. Paragon Advisors LLC now owns 37,822 shares of the company’s stock worth $1,300,000 after acquiring an additional 6,423 shares during the period. JPMorgan Chase & Co. boosted its holdings in shares of RxSight by 4.1% in the third quarter. JPMorgan Chase & Co. now owns 192,510 shares of the company’s stock valued at $9,516,000 after acquiring an additional 7,494 shares in the last quarter. Finally, Arete Wealth Advisors LLC bought a new position in RxSight during the 3rd quarter valued at $215,000. Institutional investors own 78.78% of the company’s stock.

About RxSight

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.